

Resource Summary Report

Generated by [NIF](#) on Sep 21, 2026

SNU-475

RRID:CVCL_0497

Type: Cell Line

Proper Citation

RRID:CVCL_0497

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0497

Proper Citation: RRID:CVCL_0497

Description: Cell line SNU-475 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Adult hepatocellular carcinoma

Defining Citation: [PMID:7543080](#), [PMID:8824565](#), [PMID:16616112](#), [PMID:19956504](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:23505090](#), [PMID:23887712](#), [PMID:25485619](#), [PMID:25574106](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30894373](#), [PMID:31063779](#), [PMID:31068700](#), [PMID:31378681](#), [PMID:35839778](#)

Comments: Karyotypic information: Has lost chromosome Y., Population: Korean., Part of: Seoul National University (SNU) cell line collection., Part of: MD Anderson Cell Lines Project., Part of: Liver Cancer Model Repository (LIMORE)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SNU-475

Synonyms: SNU475, NCI-SNU-475

Cross References: BTO:BTO_0003189, CLO:CLO_0009101, EFO:EFO_0002350, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-2236,

BioGRID_ORCS_Cell_line:811, BioSample:SAMN03471846, BioSample:SAMN03473134, BioSample:SAMN10987958, cancercellines:CVCL_0497, Cell_Model_Passport:SIDM01196, ChEMBL-Cells:ChEMBL3308787, ChEMBL-Targets:ChEMBL1075586, Cosmic:684201, Cosmic:871512, Cosmic:873403, Cosmic:909739, Cosmic:928145, Cosmic:2023871, Cosmic:2162533, Cosmic:2321038, Cosmic-CLP:909739, DepMap:ACH-000422, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:909739, GEO:GSM481449, GEO:GSM565920, GEO:GSM887630, GEO:GSM888715, GEO:GSM936783, GEO:GSM1670472, GEO:GSM2551590, IARC_TP53:6310, IARC_TP53:21143, IGRhCellID:SNU475, KCLB:00475, LiGeA:CCLE_299, LIMORE:SNU475, LINCS_LDP:LCL-1937, Lonza:452, PharmacDB:SNU475_1465_2019, PRIDE:PXD030304, Progenetix:CVCL_0497, PubChem_Cell_line:CVCL_0497, Wikidata:Q54955204

ID: CVCL_0497

Record Creation Time: 20220427T221552+0000

Record Last Update: 20260920T005807+0000

Ratings and Alerts

No rating or validation information has been found for SNU-475.

No alerts have been found for SNU-475.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 26 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Zheleznyak A, et al. (2026) Epithelial-Mesenchymal Transition and Stress Adaptations Underlie Yttrium-90 Resistance in Liver Cancer Cell Lines. Cancer research communications, 6(1), 178.

Yamane M, et al. (2026) H4K5 lactylation - ENO2 loop drives glycolysis and HCC progression. JHEP reports : innovation in hepatology, 8(5), 101786.

Hacioglu N, et al. (2026) Hypoxia-driven transcriptional activation of MIR100HG by HIF-1?? contributes to adaptive gene regulation in hepatocellular carcinoma. Functional & integrative genomics, 26(1).

Montoya T, et al. (2026) Alanine catabolism as a targetable vulnerability for MYC-driven liver cancer. Cell reports, 45(4), 117107.

Rose F, et al. (2026) A Serum lncRNA Signature Determines Oncogenic YAP Activity in Cancer Patients. *International journal of cancer*, 159(7), 1829.

Jang SH, et al. (2026) Epigenetic silencing of the liver-specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation. *Molecular oncology*.

Xia Y, et al. (2025) Therapeutic Potential of STE20-Type Kinase STK25 Inhibition for the Prevention and Treatment of Metabolically Induced Hepatocellular Carcinoma. *Cellular and molecular gastroenterology and hepatology*, 19(7), 101485.

Turnham RE, et al. (2025) HBV Remodels PP2A Complexes to Rewire Kinase Signaling in Hepatocellular Carcinoma. *Cancer research*, 85(4), 660.

Xiao H, et al. (2025) Viscosity regulates cell spreading and cell-extracellular matrix interactions. *The FEBS journal*, 292(4), 740.

Outla Z, et al. (2025) Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin. *Molecular oncology*.

Tang M, et al. (2024) Infiltrative Vessel Co-optive Growth Pattern Induced by IQGAP3 Overexpression Promotes Microvascular Invasion in Hepatocellular Carcinoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(10), 2206.

Kato H, et al. (2024) Histone methyltransferase SUV420H1/KMT5B contributes to poor prognosis in hepatocellular carcinoma. *Cancer science*, 115(2), 385.

Breitenecker K, et al. (2023) Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma. *Frontiers in oncology*, 13, 1238883.

Azbazdar Y, et al. (2023) Comparative membrane lipidomics of hepatocellular carcinoma cells reveals diacylglycerol and ceramide as key regulators of Wnt/??-catenin signaling and tumor growth. *Molecular oncology*, 17(11), 2314.

Gong X, et al. (2023) Volumetric Compression Shifts Rho GTPase Balance and Induces Mechanobiological Cell State Transition. *bioRxiv : the preprint server for biology*.

Uong TNT, et al. (2023) Direct Tumor Irradiation Potentiates Adoptive NK Cell Targeting Against Parental and Stemlike Cancer in Human Liver Cancer Models. *International journal of radiation oncology, biology, physics*.

Zhao Z, et al. (2023) QKI shuttles internal m7G-modified transcripts into stress granules and modulates mRNA metabolism. *Cell*, 186(15), 3208.

Lee SY, et al. (2022) Sorbitol dehydrogenase induction of cancer cell necroptosis and macrophage polarization in the HCC microenvironment suppresses tumor progression. *Cancer letters*, 551, 215960.

Missiaen R, et al. (2022) GCN2 inhibition sensitizes arginine-deprived hepatocellular carcinoma cells to senolytic treatment. *Cell metabolism*, 34(8), 1151.

Yang C, et al. (2022) A survey of optimal strategy for signature-based drug repositioning and an application to liver cancer. *eLife*, 11.